Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550725 | PMC |
| http://dx.doi.org/10.1016/j.esmoop.2024.103974 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Thrombomodulin Improved Disseminated Intravascular Coagulation After Cardiac Surgery.
Ann Thorac Surg Short Rep
June 2023
Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Background: Disseminated intravascular coagulation (DIC) is a fatal complication in postoperative patients. Recombinant human thrombomodulin (rhTM) has been used to treat DIC in some settings; however, the use of rhTM as a therapy for DIC has not been established in the field of cardiovascular surgery. This study aimed to investigate the efficacy and optimal timing of rhTM treatment in patients with DIC after cardiovascular operation.
View Article and Find Full Text PDFAssessing the impact of evolocumab on thin-cap fibroatheroma and endothelial function in patients with very high-risk atherosclerotic cardiovascular disease: a study protocol for a randomized controlled trial.
Cardiovasc Diagn Ther
December 2024
Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Engineering Research Center of Cardiovascular Wisdom Diagnosis and Treatment, Beijing, China.
Background: The prevalence of very high-risk atherosclerotic cardiovascular disease (ASCVD) is significant in China, with suboptimal rates of low-density lipoprotein cholesterol (LDL-C) compliance exacerbating plaque instability and causing a higher incidence of major adverse cardiac events (MACEs). Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are effective in reducing LDL-C levels, increase the stability of vulnerable plaque, and influence the progression of atherosclerosis through multiple mechanisms as demonstrated in animal studies. However, there is currently a lack of evidence regarding the efficacy and safety of high-intensity statin therapy combined with PCSK9i in the secondary prevention of ASCVD in the Chinese population.
View Article and Find Full Text PDFValidation of a non-invasive filling pressure (NIFP) device for measuring cardiac pressure and assessing congestion levels in patients with heart failure.
Int J Cardiol
January 2025
State Key Laboratory for Innovation and Transformation of Luobing Theory, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address:
Background: Heart failure (HF) is a high-burden clinical syndrome characterized by intravascular and extravascular congestion, impacting patients' outcomes. Current diagnostic methods for assessing intravascular congestion, including right heart catheterization (RHC), have some limitations. There is a need for accurate, stable, and widely applicable non-invasive measurement methods to improve HF diagnosis and treatment.
View Article and Find Full Text PDFPurpura fulminans (PF) is a rare but devastating complication of sepsis characterized by a highly thrombotic subtype of disseminated intravascular coagulation (DIC). A medical emergency, PF cases often require the involvement of consultant hematologists to assist with diagnosis and management of patients who are in a highly dynamic and deteriorating clinical situation. Patients who survive past the first 24 to 72 hours often die from complications of unchecked thrombosis rather than from shock, and survivors are usually left with severe scarring and tissue loss.
View Article and Find Full Text PDFTranscatheter Caval Implantation for Severe Tricuspid Regurgitation.
Curr Cardiol Rep
January 2025
Department of Cardiovascular Medicine, Heart Vascular & Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH, 44195, USA.
Purpose Of Review: We describe the evolution of caval valve implantation (CAVI) as a treatment for severe symptomatic tricuspid regurgitation (TR) in the high surgical risk patient.
Recent Findings: Surgical treatment of severe TR is often limited by the high surgical risk of the patients who tend to develop severe secondary TR. Coaptation, annuloplasty, and orthotopic replacement strategies are all limited by annular and leaflet geometry, prior valve repair, and the presence of cardiac implantable device leads.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!